Trial Management Group
|CEC.6 (Alliance N0577) - Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma - was centrally activated on March 22.
The primary goal of this trial is to determine whether patients who receive radiotherapy with concomitant temozolomide followed by adjuvant temozolomide (RT + TMZ → TMZ) (ARM B) have a marginally better progression free survival (PFS) as compared with patients who receive radiotherapy followed by adjuvant PCV chemotherapy (RT → PCV) (ARM A).
Trial sample size is 360 patients.
Centres wishing to participate on this study should contact Sarah Hunter, Study Coordinator, at email@example.com. The trial website can be found here ... https://www.ctg.queensu.ca/trials/brain/cec6/
MAC.18 (IBCSG18-14/Alliance 221405) - A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women with Endocrine Responsive Breast Cancer who Desire Pregnancy (POSITIVE) - as centrally activated on March 16.
The primary objective of the trial is to assess the risk of breast cancer relapse associated with temporary interruption of endocrine therapy (ET) to permit pregnancy. The secondary objective
is to evaluate factors associated with pregnancy success after interruption of ET.
The primary endpoint is breast cancer free interval (BCFI) defined as the time from enrollment in the study to the first invasive BC event (local, regional, or distant recurrence or a new invasive contralateral BC).
Trial sample size is 500 patients.
Centres wishing to participate on this trial should contact Wenling Liu at firstname.lastname@example.org. The trial website can be found here ... https://www.ctg.queensu.ca/trials/breast/mac18.